Skip to main content

Our objective

Despite the global burden of cardiovascular disease, the development of new cardiovascular drugs has stalled for over two decades. The primary reason is intolerance to drug-related side effects. Recently, there has been considerable interest in the development of natural supplements for cardiovascular-protective therapeutics owing to their inherent safety profiles and the clinical evidence for ameliorating chemotherapy-induced cardiovascular complications. However, it remains a huge challenge to understand the cardiovascular-protective mechanisms at the molecular level, which impedes pharmacological optimisation of these bioactive agents for therapeutic use. Therefore, we aim to apply cutting-edge chemoproteomics platforms to understand the intricate signalling interplay in cardiomyocytes in response to different natural products and to construct a comprehensive chemotype database for cardiovascular-protective drug discovery.